Dr Reddys Laboratories, an integrated global pharmaceutical company, announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.
It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.
The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.
Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).